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The tat gene is required by HIV-1 for efficient reverse transcription and this function of Tat can be distinguished from its
role in transcription by RNA polymerase II using tat point mutations that abrogate each function independently. The
mechanism of Tat’s role in reverse transcription, however, is not known, nor is it known whether this role is conserved among
trans-activating factors in other retroviruses. Here we examine the abilities of heterologous viral trans-activating proteins
from jembrana disease virus (jTat), HIV-2 (Tat2), and equine infectious anemia virus (eTat) to substitute for HIV-1 Tat (Tat1)
and restore reverse transcription in HIV-1 carrying an inactivated tat gene. Natural endogenous reverse transcription assays
showed that trans-activators from some retroviruses (Tat2 and jTat, but not eTat) could substitute for Tat1 in complemen-
tation of HIV-1 reverse transcription. Finally, we show that Y47 is critical for Tat1 to function in reverse transcription, but not
HIV-1 gene expression. We mutated the homologous position in jTat to H62Y and found it did not improve its ability to
stimulate reverse transcription, but an H62A mutation did inhibit jTat complementation. These data highlight the finding that
the role of Tat in reverse transcription is not related to trans-activation and demonstrate that other tat genes conserve this
function. © 2002 Elsevier Science (USA)INTRODUCTION
Reverse transcription is the process by which retrovi-
ruses convert their positive-sense single-stranded RNA
genome into a double-stranded DNA copy (Baltimore,
1970; Temin and Mizutani, 1970). Reverse transcription
requires, at a minimum, viral genomic RNA containing
the primer binding site (PBS), a cellular tRNA molecule
with a 3 sequence complementary to the PBS, the virally
encoded reverse transcriptase, and deoxynucleotides
(Taylor, 1977). The combined work of many laboratories
has shown, however, that multiple factors regulate HIV-1
reverse transcription; these factors include RNA struc-
tures and several viral proteins. Interactions between an
A-rich loop upstream of the viral PBS and the anticodon
loop of tRNAlys3 are required for the formation of an
efficient reverse transcription initiation complex, and
subtle disruptions of upper TAR RNA structure can inhibit
reverse transcription (Harrich et al., 2000; Isel et al.,
1999). Vif appears to affect reverse transcription by al-
tering the structural stability of the viral core and RNA,
while Nef is thought to affect early post-entry events
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226such as uncoating (Aiken and Trono, 1995; Dettenhofer et
al., 2000; Ohagen and Gabuzda, 2000; Schwartz et al.,
1995; Zhang et al., 2000). NCp7 also affects early steps in
reverse transcription, including primer placement onto
the PBS and the first template switching of reverse tran-
scription (Allain et al., 1994; Huang et al., 1998; You and
McHenry, 1994). Finally, Tat improves the efficiency of
negative-strand () strong-stop DNA (ssDNA) synthesis
and genetic analysis showed that this role was distinct
from its well-characterized role in upregulation of HIV-1
transcription by RNA polymerase II (RNAPII) (Ulich et al.,
1999). Whether Tat acts during the initiation reaction or
an early event such as uncoating is not known.
Virtually all complex retroviruses encode within their
genome a trans-acting transcriptional activator protein
that can increase RNAPII-mediated transcription from a
proviral promoter located in the 5 long terminal repeat
(LTR) (reviewed in Rabson and Graves, 1997). These
proteins can be divided into two broad categories. T cell
leukemia virus (HLTV), bovine leukemia virus (BLV), ca-
prine arthritis encephalitis virus (CAEV), and human
foamy virus (HFV) transactivator proteins directly or indi-
rectly target DNA sequences in the viral LTR, while HIV-1,
HIV-2, simian immunodeficiency virus (SIV), bovine im-
munodeficiency virus (BIV), jembrana disease virus (JDV),Key Words: human immunodeficiency virus; tat; Jembrana
tion; transcription.
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and equine infectious anemia virus (EIAV) use transacti-
vator proteins called Tat that target newly transcribeddisea
promoter-proximal viral RNA structures referred to as the
trans-activation response (TAR) RNA. While the precise
mechanism of activation varies between different activa-
tors, all act in conjunction with cellular proteins to in-
crease transcription of viral RNA. Proteins in the DNA-
target category generally act in conjunction with, and
enhance the function of, cellular transcription factors. In
general, these viral activators, such as Tax (HTLV/BLV
family) and Bel-1 (HVF), act through DNA and increase
the transcription initiation rate from the viral promoter.
Tat proteins, with the exception of CEAV Tat, which has a
DNA target, have a very different mechanism of action.
The interactions between various Tat proteins and their
cognate TAR RNAs have been recently reviewed (Jones,
1997; Taube et al., 1999). Briefly, HIV-1, BIV, and EIAV Tat
can bind to their respective TAR RNAs in conjunction
with the species-appropriate cyclin T1. For example,
HIV-1 Tat (Tat1) recruits cyclinT1/CDK9, which together
form pTEFb (TAK/PITALRE), following TAR RNA synthesis
by RNAPII; pTEFb then phosphorylates the RNAPII C-
terminal domain and begins the transition from transcrip-
tion initiation to elongation. Although significant differ-
ences exist with respect to specific structure-function
and TAR recognition, the underlying activation mecha-
nism of recruitment of a cyclin-dependent kinase to the
viral promoter is conserved across a range of Tat pro-
teins.
In a previous study, we showed that Tat1 is required
for efficient HIV-1 reverse transcription and that the
mechanism of this Tat1 function is trans-activation-inde-
pendent (Ulich et al., 1999). We now extend these studies
by examining whether tat genes from other lentiviruses
can functionally substitute for Tat1. We expressed eTat,
jTat, and Tat2 in a previously characterized 293 cell line
stably transfected with an HIV-1 provirus lacking func-
tional tat. We assayed the natural endogenous reverse
transcription capacity of the resulting trans-comple-
mented viruses and found that Tat2 and jTat, but not eTat,
could partially restore HIV-1 reverse transcription. Our
results suggest that other lentiviral tat genes conserve
this function in reverse transcription. Next, we investi-
gated whether Tat amino acid residue Y47, which is
reported to support robust transactivation but which im-
parts a replication defect (Verhoef et al., 1997), had a
reverse transcription defect. We found that a mutation to
Y47A imparted a large defect in reverse transcription
equivalent to that observed in the absence of Tat. A
mutation at the homologous position in jTat, H62A, also
slightly decreased reverse transcription levels, but did
not affect the level of transactivation of HIV-1 by jTat.
Thus, Tat Y47A further segregates the role of Tat in
reverse transcription from transactivation and indicates
that a function in reverse transcription may be conserved
by other lentiviral transcriptional activator proteins.
RESULTS
Analysis of HIV-1tat cell lines transiently and stably
expressing various tat genes
An alignment of the predicted amino acid (aa) se-
quences of the tat genes used in this study showed that
all four Tat proteins have a conserved core domain (Fig.
FIG. 1. Alignment of the predicted aa sequences of lentivirus tat genes. Tat2, jTat, and eTat are compared to Tat1 and residues that match Tat1
exactly are boxed. Residues shared by all tat genes are shaded yellow; exact matches within the carboxy terminus are shaded red, and basic residues
in the carboxy domain that are not exact matches to Tat1 are underlined in green. Dashes represent gaps introduced to optimize the alignment, which
was generated by the Jotun Hein method using DNASTAR MegAlign software v1.02.
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1, yellow boxes), as well as an arginine-rich carboxy-
terminal domain (Fig. 1, red boxes and underlined in
green), which is required for RNA binding and nuclear
localization. In addition, the jTat, Tat1, and Tat2 proteins
share at least six of seven cysteine residues, while the
amino-terminal domains of Tat1, Tat2, and eTat are rich in
acidic aa residues. In contrast, the amino terminus of jTat
lacks acidic residues but is very glycine-rich (7 of the first
21 aa).
Two human cell lines, HeLa and 293, were transfected
with pBKRSV containing these tat genes. Each tat gene
or the parental vector was transfected into HeLa cells
along with an HIV-1 LTR-driven CAT expression plasmid
and an SV40 promoter-driven -galactosidase expres-
sion vector. The levels of CAT activity in lysates obtained
from the transfected cells were measured by ELISA.
These values were normalized to total protein and the
level of -galactosidase activity in each lysate. As shown
in Fig. 2A, CAT levels were substantially increased by
Tat1, jTat, and Tat2, in that order of transactivation effi-
ciency. The HIV-1 LTR promoter was not activated by
eTat: CAT levels in the presence of eTat were equivalent
to basal levels of gene expression. Next, a previously
described 293 cell line stably transfected with an HIV-1
provirus carrying a nonfunctional tat gene (293HIV1tat)
was transfected with pBKRSV-tat constructs, or with the
empty parental vector as a control. Culture supernatant
was collected 48 h posttransfection and assayed for
HIV-1 CA-p24 Ag by ELISA. Both Tat2 and jTat increased
HIV-1 gene expression but at reduced levels compared
to Tat1, while eTat had no effect (Fig. 2B). These results
are in agreement with other reports on the ability of
various tat genes to activate the HIV-1 promoter (Arya et
al., 1987; Carroll et al., 1991; Chen et al., 2000).
The transfected 293HIV1tat cells were serially di-
luted so that single cells could be plated and grown in
culture media supplemented with G418 and puromycin.
The HIV1tat provirus conveys puromycin resistance
while pBKRSV conveys G418 resistance. The cell cul-
tures were expanded and supernatants were assayed
for HIV-1 CA-p24 Ag. Four double-stable G418/puromy-
cin-resistant cell lines were selected for further charac-
terization on the basis of cell viability and CA-p24 ex-
pression levels. The introduced tat gene and the proviral
DNA containing the mutated tat-encoding region were
amplified separately from isolated chromosomal DNA by
PCR and the integrity of both were confirmed by se-
quencing (data not shown). After 24 h on 10-cm dishes,
the 293HIV1tat:pBKRSV (vector control) cells produced
2 to 3 ng/ml CA-p24 Ag, while 293HIV1tat:Tat1 cells
made 100 to 130 ng/ml CA-p24 Ag, confirming that tat1
was functional. The stable 293HIV1tat cell lines com-
plemented with jTat or Tat2 produced quantities of CA-
p24 Ag that were proportional to those observed follow-
ing transient transfection, that is, Tat1  jTat  Tat2 
eTat in terms of transactivation efficiency (Fig. 2C). Sur-
prisingly, the 293HIV1tat:eTat double-stable cells made
approximately two- to fivefold higher levels of CA-p24 Ag
than 293HIV1tat:pBKRSV. The elevated levels of virus
made by the eTat cell line are unexpected and not easily
explained, as transient expression of eTat failed to acti-
vate HIV-1 gene expression. Of the 48 293HIV1tat:
pBKRSV cell lines screened for HIV-1 production, none
made virus at levels exceeding the parental cell line.
To confirm that tat genes were transcribed in the
double-stable cell lines, ribonuclease protection assays
were performed. Total RNA was obtained from two rep-
resentative stably transfected cell lines and tat expres-
sion was assayed by RNA protection using gene-specific
antisense RNA probes. Total RNA from 293HIV1tat:Tat1
FIG. 2. Activation of HIV-1 gene expression by different lentivirus tat genes. (A) HeLa cells were transfected with a eucaryotic expression vector
containing Tat1, eTat, jTat, or Tat2 along with an HIV-1 LTR-CAT reporter plasmid and pCH110. The amount of CAT protein induced in cells expressing
each tat gene is shown relative to cells transfected with empty parent vector. (B) 293HIV1tat cells were transfected with the same vectors. CA-p24
Ag present in the culture supernatant was measured by ELISA and used to determine the level of induction due to each tat gene. The results from
all transient transfections are normalized to a -galactosidase activity as described under Materials and Methods. (C) Clonal stable cell lines were
isolated from the transiently transfected 293HIV1tat cells, and the amount of CA-p24 Ag made by each cell line was measured by ELISA; at least
three stable cell lines were isolated for each tat gene, and two representative results are shown.
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cells yielded multiple protected RNA species because
the proviral tat gene is derived from the HIV-1BH10 strain
(and contains a 14-bp deletion), while the introduced tat
gene is derived from the HIV-1SF2 strain. As shown in Fig.
4, mismatched nucleotide sequences between the
650-bp SF2 tat antisense probe (Fig. 3, top arrow) and
BH10 tat protected two predicted 36 and 46 nt RNA
fragments (Fig. 3A, bottom arrow and Fig. 4), while SF2
tat mRNA protected an expected 256-nt RNA fragment
(Fig. 3A, middle arrow). Several other protected species
were observed; some are nonspecific bands also pro-
tected in the negative control yeast RNA lane. The others
were most likely partial SF2 tat probe RNA digestion
products. PhosphorImager analysis indicated that the
HIV-1 RNA steady-state levels were approximately nine-
fold higher in the presence of Tat1 than in control
pBKRSV-transfected cell lines (Fig. 3A, 293HIV1tat:Tat1
versus 293HIV1tat). Several nonspecific RNA species
protected by the Tat1 probe hybridized to total yeast RNA
were also apparent in total RNA from 293HIV1tat and
Tat1-complemented 293HIVtat cells (Fig. 3). Ribonucle-
ase protection assays were also performed using total
RNA isolated from double-stable cell lines and eTat, jTat,
or Tat2 gene-specific riboprobes as shown (Figs. 3B–3D).
An RNA species of the expected size was protected from
RNase digestion in total RNA from the double-stable cell
lines, but not in control RNA isolated from 293HIV1tat or
in total yeast RNA, confirming the expression of the
stably transfected tat genes (Figs. 3B–3D). All total RNA
preparations were also analyzed with an actin-specific
RNA probe, which confirmed that RNA of similar integrity
and quantity was used in all of the assays (Fig. 3E).
Analysis of Tat trans-complemented viruses:
Virion proteins, RNA, natural endogenous
reverse transcription
Culture supernatant was collected from each stably
transfected cell line and virions were pelleted through
20% sucrose by ultracentrifugation. The viruses were
suspended in complete IMDM and assayed in triplicate
for total RT activity and CA-p24 levels by ELISA. As
shown in Fig. 4, the CA-p24 Ag:RT ratios indicated that no
gross defects in virion production were present. Virion
RNA was extracted from equivalent amounts of virus and
quantitated by ribonuclease protection assay (Fig. 5B).
FIG. 3. Ribonuclease protection assay of total RNA using a gene specific probe. Total RNA isolated from the parental 293HIV1tat cell line or each
double-stable 293HIV1tat cell line was incubated with a tat-specific antisense RNA probe for (A) Tat1, (B) jTat, (C) Tat2, and (D) eTat, or to a
gamma-1-actin antisense RNA probe (E) as indicated. The probes were incubated with yeast RNA in the presence or absence of RNase A/T1 as
shown and the products of the reactions were separated on a 5% denaturing polyacrylamide gel. The dried gels were visualized and quantitated on
a Molecular Dynamics phosphorImager using ImageQuant v1.2 software. tat  293HIV1tat.
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PhosphorImager analysis showed that the virion RNA
levels differed by less than twofold. No specific protected
RNA was detected in control reactions using the anti-
sense probe or total RNA isolated from yeast (not
shown).
We used PCR to measure the amounts of negative-
strand () strong-stop DNA synthesized by each of the
trans-complemented viruses in natural endogenous re-
verse transcription (NERT) reactions (Zhang et al., 1998)
and expressed the NERT capacity of each virus relative
to the wild-type. Viruses from four different cloned cell
lines were assayed and the results from two represen-
tative experiments are shown (Fig. 6). We found that virus
lacking Tat1 (tat) had an approximately fourfold lower
capacity to synthesize () ssDNA than virus produced in
cells making Tat1. Virus made in cells expressing eTat
was similarly deficient in () ssDNA synthesis, while jTat
and Tat2 partially or completely restored () ssDNA
synthesis. Some variability in the degree of reverse tran-
scription restoration was observed, as some jTat (one of
four stable cell lines, data not shown) and Tat2 (two of
four stable cell lines, one shown) trans-complemented
virus stocks showed reverse transcription efficiencies
equivalent to virus trans-complemented with Tat1 (Fig. 6).
We have previously reported up to 25-fold reverse tran-
scription defects in HIV-1 lacking Tat (Ulich et al., 1999),
a substantially greater defect than was observed in this
study. This difference may be explained by changes in
methodology. We have recently described significant im-
provements in the NERT-PCR assay, using fewer cycles
of PCR to accurately amplify control DNA over a 16- to
32-fold linear copy number range (Hooker et al., 2001).
This provides significantly greater accuracy than previ-
ous assays which estimated copy number from DNA
controls spanning a 1000-fold range (Harrich et al., 1997;
Ulich et al., 1999). Further, in the present study total RT
levels in virus stocks were quantitated using twofold
serial dilutions, which provides greater accuracy than
the single measurements used in earlier studies. We
have subsequently performed NERT-PCR assays on vi-
rus made by the original 293HIV1tat cell line and ob-
served reproducible five- to eightfold defects in ()
ssDNA levels (data not shown) (Harrich et al., 1997),
compared to the fourfold reverse transcription defect
observed for 293HIV1tat:pBKRSV in the present study.
Finally, because transient expression of Tat2 and eTat in
293HIVtat yielded insufficient levels of virus for NERT/
PCR analysis, stable cell lines were isolated. As the
mechanism of Tat-enhanced reverse transcription is still
unknown, it is possible that a stably integrated parental
or Tat expression plasmid somehow altered the cellular
milieu in such a way as to improve reverse transcription.
FIG. 4. Nucleotide sequences of tat genes from HIV-1SF2 and HIV-1BH10. Mismatches in the nucleotide sequences of the tat genes are indicated by
block boxes shown above the sequence. The open box indicates a nucleotide mismatch in which the SF2 antisense probe sequence would be
adenosine and not cleaved by ribonuclease activity in the protection assays shown in Fig. 3A. The grey boxes indicate the two longest contiguous
BH10 tat sequences nt 55 to 90 (36 total nt) and nt 112 to 157 (46 total nt) which protected an SF2-derived antisense RNA probe from ribonuclease
digestion. These two protected RNA fragments are shown in Fig. 3A (bottom arrow).
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Virtually no () ssDNA was detected in virus not sup-
plied with dNTPs (Fig. 6C), and all PCR reactions were
performed over a copy number range within which linear
standard curves showed correlation coefficients (r2) of
0.99 or higher (Figs. 6E and 6D). All NERT-PCR assays
were performed twice and gave similar results. Together,
these data demonstrate that different Tat proteins from
some, but not all, lentiviruses have the capacity to im-
prove the efficiency of HIV-1 () strong-stop DNA syn-
thesis, as was previously reported for Tat1.
It has been argued that the ability to trans-complement
HIV-1 reverse transcription generally correlates with the
ability of Tat1 to activate HIV-1 gene expression. However,
certain aa substitutions in Tat1 have been shown to down-
regulate transactivation as well as virus replication. Verhoef
et al. (1997) showed that Tat1 with a Y47H or Y47A substi-
tution maintained 45 to 95% of wild-type transactivation
levels depending on the cell type used, but that virus with
Y47H Tat had markedly delayed replication kinetics. They
speculated that this was due to other biological roles
played by Tat (Huang et al., 1994). Therefore, we first mea-
sured HIV-1 trans-activation by Tat1 Y47A in 293 and 293T
cells (not tested by Verhoef et al.) and found 50 to 70% of
wild-type transactivation levels (data not shown). As shown
in Fig. 1, Tat1 aa 47, Tat2 aa 76, and eTat aa 49 all have Y
adjacent to the LGI motif (in yellow), while jTat has H in this
position. The UAU codon for H and can bemutated to Y with
a single base change to CAU. Therefore, we mutated jTat
H62 to Y or A and transfected the wild-type or mutated jTat
genes, and Tat1 or Tat1-Y47A genes into 293HIV1tat cells,
and the supernatants were harvested 48 h posttransfection.
We found that all of these tat genes activated HIV-1 gene
expression to the levels shown in Fig. 2A, and no differ-
ences in transactivation levels were observed between
wild-type, H62Y, and H62A jTat expression plasmids (data
not shown). Next, we performed NERT/PCR assays on the
viruses. As shown in Fig. 7, Tat1-Y47A did not complement
() ssDNA synthesis. This mutated tat gene has a unique
and previously undescribed phenotype which supports
HIV-1 transactivation in 293HIV1tat cells but does not
support efficient reverse transcription in the virus made by
these cells compared to the same cells supplied wild-type
Tat supporting a direct role for Tat in reverse transcription.
Again, jTat showed some ability to complement () ssDNA
synthesis; this effect was not improved by jTat-H62Y, but
was (albeit slightly) inhibited by jTat-H62A. Subsequently,
we have introduced into HIV-1 NL4-3 proviral DNA tat1
genes in which Y47 is mutated to H or D residues while
conserving the rev gene reading frame. The resulting vi-
ruses have significantly diminished replication capacity and
measurable reverse transcription defects (D. Harrich and A.
Apolloni, unpublished observations). It is very likely that the
delayed replication by HIV-1 with Tat1 Y47H that was ob-
served by Verhoef et al. was at least partly due to a defect
in reverse transcription.
DISCUSSION
The precise role played by Tat1 in reverse transcrip-
tion is still unknown. In the present study, we made HIV-1
in the absence of Tat1 and found that Tat proteins from
other lentiviruses could substitute for HIV-1 Tat in sup-
port of reverse transcription, indicating that tat genes
from other lentiviruses conserve this function. Current
information on Tat’s role in reverse transcription is based
on genetic studies that segregate this function from Tat’s
better characterized role in transcriptional activation of
the HIV-1 LTR promoter (Ulich et al., 1999). Single exon
FIG. 5. Analysis of partially purified virus. Virus was pelleted through
a 20% sucrose cushion by ultracentrifugation and resuspended in
serum free medium. (A) The amount of CA-p24 Ag (in ng/ml) and total
reverse transcriptase activity (in U/ml) were measured and compared
in each culture supernatant. All assays were performed in triplicate and
the standard deviations from the mean are shown. (B) Ribonuclease
protection assay of virion RNA. Virion RNA was isolated from pelleted
virus (normalized to CA-p24 Ag) along with a radiolabeled antisense
RNA probe which encompassed the HIV-1 5 major splice donor site,
and yeast total RNA. The RNA mixture was digested with RNase A/T1
and the products were separated on a 5% denaturing polyacrylamide
gel. An RNA species of the expected size was observed in virion RNA
preparations as indicated (arrow).
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Tat1 can be divided into four domains: an activation
domain composed of a proline/acidic-rich region, a cys-
teine-rich region, a highly conserved core domain con-
taining a KXLGI (where X is any aa) motif which is wholly
(jTat, Tat2, BIV Tat [bTat], and SIV Tat) or partially (eTat)
conserved in other lentivirus Tat proteins, and an argi-
nine/lysine-rich region which is required for RNA binding
and nuclear localization. Our previous studies showed
that each domain of Tat1 contributed toward comple-
mentation of HIV-1 reverse transcription. For example,
reverse transcription was not stimulated by mutant Tat1
in which the N-terminal acidic or proline residues were
changed to glycine or leucine, respectively (Ulich et al.,
1999). The ability of jTat to increase HIV-1 reverse tran-
scription was therefore unexpected and significant,
given the differences between jTat and Tat1 over this
domain. Chen et al. (2000) recently found that jTat sup-
ported HIV-1 gene expression and replication both in cell
lines and in activated primary T-cells, but with reduced
kinetics and fitness. Verhoef et al. introduced mutated tat
genes into the HIV-1Lai isolate and compared virus rep-
lication with Tat transactivation of the HIV-1 LTR pro-
FIG. 6. Representative NERT assay of HIV1tat virus produced by double-stable 293HIV1tat cells expressing different tat genes. NERT assays
were performed on at least four independent virus stocks and two representative results are shown. (A) PCR was used to quantitate the level of ()
strong-stop DNA synthesized in NERT reactions by tat virus and by tat virus made in cells expressing Tat1, eTat, jTat, and Tat2 as indicated. (B)
PhosphorImager analysis of the PCR shown in (A); data are expressed as a percentage of the maximum amount of () ssDNA measured. (C) Negative
controls: the same NERT assays as in (A), but without addition of dNTPs. (D) PCR standard curve generated using an HIV-1 proviral plasmid. (E)
PhosphorImager analysis of the gel shown in (D); r2  0.991.
FIG. 7. NERT assay of virus obtained after transient expression of
wild-type or mutated Tat1 and jTat. 293HIV1tat cells were transfected
with tat expression plasmids as indicated and the culture medium was
changed after 24 h. Culture supernatant was collected after an addi-
tional 24 h and assayed for total RT activity. Equal amounts of virus
were assayed by NERT-PCR as previously described. These experi-
ments were performed twice and the mean value and standard devia-
tion is shown.
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moter. They found that as little as a twofold reduction in
Tat activity affected viral fitness. HIV-1Lai carrying certain
Tat1 mutations (Y26F, Y26W, F32W, Y47H), however, ac-
tivated HIV-1 gene expression at 75 to 100% of the level
obtained with wild-type Tat1 but still showed reduced
viral fitness. We show in these experiments that the Y47A
Tat mutant, which also has near-wild-type transactivation
ability, does not support efficient reverse transcription.
Our data indicate that this reduced viral fitness observed
by Verhoef et al., and in HIV-1 expressing jTat, was likely
due to combined inefficiencies in transcription and re-
verse transcription.
Recently, Kameoka et al. (2001) performed experiments
with N-terminal histidine-tagged recombinant Tat, using ei-
ther the 1-exon encoding 72 aa form or the 2-exon 86, or 101
aa forms. They added these Tat proteins to in vitro reverse
transcription reactions and found that the 2-exon forms of
Tat actually inhibited reverse transcription, while 1-exon Tat
had no effect on the reaction. Also, viruses that are capable
of making only make 1-exon Tat have markedly reduced
replication kinetics compared to HIV-1 making 2-exon Tat, a
result that is somewhat complicated by the fact that 1-exon
Tat virus, but not the 2-exon Tat virus, lacked Nef in these
experiments. Nef is important for virus replication and ap-
pears to influence virion maturation, affecting replication
during early events such as entry, uncoating, or reverse
transcription. Nevertheless, that 2-exon-Tat is an excellent
inhibitor of in vitro reverse transcription as well as of deter-
gent-solubilized virus, suggests that inclusion of 2-exon Tat
in the virion would be detrimental to virus replication. This
does not exclude a direct role for 1-exon Tat in reverse
transcription, since both 1- and 2-exon forms of Tat are
made in natural infection.
Virtually all lentivirus Tat proteins bind their respective
TAR RNA elements; an unpaired U within the RNA stem
is often involved in the binding (TAR1, TAR2, SIV TAR,
jTAR, and BIV TAR [bTAR]), except for eTat, which binds a
central loop and adjacent nucleotides within eTAR. The
arginine-rich domain of Tat is responsible for RNA bind-
ing, and many studies have shown that arginine peptides
bind various TAR RNA structures. For example, a BIV
Tat65–81 peptide which binds to bTAR will also bind to
TAR1, but with a 20- to 200-fold lower affinity (Smith et al.,
2000). The exception, again, is eTat. Although its basic
domain is quite similar to that of other Tat proteins, eTat
requires the entire 26 aa C-terminal region of the protein
to bind eTAR, and binding of eTat to HIV-1 TAR has not
been reported. Genetic mapping of Tat1 regions neces-
sary to support its role in reverse transcription showed
that an intact basic domain was important (Harrich et al.,
1997; Ulich et al., 1999). A C-terminal deletion to aa 53
could not support reverse transcription, whereas substi-
tution of aa 50 to 57 with glycine or alanine retained
partial function. As the latter tat mutant retains an argi-
nine at position 49, it may bind TAR1 but with reduced
affinity. We are currently evaluating the effects on HIV-1
reverse transcription of Tat1 protein lacking all or spe-
cific combinations of arginine residues (unpublished ob-
servations).
In summary, these experiments show that Tat proteins
from other lentiviruses have some ability to facilitate HIV-1
reverse transcription and that this role is independent of the
role of Tat in activation of gene expression. All of these
observations imply that Tat is a virion protein, but repeated
attempts to detect Tat in purified virions have so far been
unsuccessful. Very few molecules of Tat would be present
per virion if TAR (a maximum of four structures per virion,
two per genomic RNA molecule) recruits this primarily nu-
cleolar protein to virus budding at the cell membrane. In-
terestingly, heterokaryon assays in which one progenitor
cell made Tat–green florescent protein (GFP) fusions
showed that Tat-GFP could traffic between nuclei in the
absence of de novo protein synthesis, supporting the pos-
sibility of Tat function(s) in environments outside the cell
nucleus (Stauber and Pavlakis, 1998). The lessons learned
in detecting virion Vif protein indicates that the presumed
low levels of virion Tat will make its discovery extremely
difficult and controversial.
MATERIALS AND METHODS
Cell lines, viruses, and infections
All cells were incubated at 37°C in a humidified 5%
CO2 atmosphere. The method by which stable cell lines
were generated is described in detail elsewhere (Ulich
et al., 1999). Briefly, 293 cells stably transfected with
an HIV-1 provirus lacking a functional tat gene
(293HIV1tat) were cotransfected with pBKRSV (Strat-
agene, La Jolla, CA) containing eTat, jTat, or Tat2 along
with an SV40 -galactosidase control plasmid (pCH110,
Amersham Pharmacia Biotech). A 293HIV1tat cell line
stably expressing Tat1 was previously described (Har-
rich et al., 1997). The transfected cells were serially
diluted 48 h posttransfection in Iscove’s modified DMEM
(IMDM) supplemented with 1% penicillin-streptomycin, 1
mM Glutamax, 5% newborn calf serum, 2% fetal bovine
serum (complete IMDM) plus 800 g/ml G418 sulfate
(Life Technologies, Melbourne, VIC) and 0.25 g/ml pu-
romycin (Sigma-Aldrich). An aliquot of the transfected
cells were saved and lysates were prepared for total
protein and -galactosidase activity assays. Individual
cell foci were isolated and expanded, and supernatant
from each culture was assayed for HIV-1 CA-p24 antigen
(Ag). Cell lines that produced CA-p24 Ag were charac-
terized further.
Virus stocks were produced and assayed as previ-
ously described (Ulich et al., 1999). Briefly, 293 cell lines
were grown in 100-mm tissue culture dishes in complete
IMDM supplemented with 500 g/ml G418 sulfate and
0.25 g/ml puromycin (Sigma-Aldrich). When the cells
reached 50% confluency, the supernatant was replaced
with complete IMDM lacking G418-sulfate or puromycin
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and the plates were incubated for a further 18–24 h. The
medium was collected, filtered through a 0.45-m PES
membrane, and stored in aliquots at80°C. Virus stocks
were assayed for HIV-1 CA-p24 Ag using a commercial
ELISA (NEN Life Science Products, Baltimore, MD) and
for total RT activity using the RT Detect Assay (Roche
Diagnostics Australia, Castle Hill, NSW). RT Detect as-
says were performed on serial twofold dilutions of fil-
tered virus stocks to ensure at least two dilutions fell
within the range of the standard curve.
Plasmids and constructs
The equine infectious anemia virus (EIAV) tat gene
(etat) was a kind gift from David Derse (National Insti-
tutes of Health); HIV-2rod tat gene (tat2) was a kind gift of
Richard Gaynor (University of Texas Southwestern Med-
ical Center), and jembrana disease virus tat gene (jtat)
was a kind gift of Ming Wei (Sir Albert Sakzewski Virus
Research Centre). The HIV-1 tat gene (tat1) from the SF2
isolate was previously described (Ulich et al., 1999). The
tat genes were ligated into pBKRSV (Stratagene, La Jolla,
CA) and pGem3z (Promega Australia, Annandale, NSW)
and confirmed by DNA sequencing using the Sequenase
system (Amersham Pharmacia Biotech Pty. Ltd., Annan-
dale, NSW). An HIV-1 genomic RNA probe was made
using sequences from 113 to 553 from HIV-1SF2
(where 1 indicates the transcription start site) which
were ligated into pGem4z. QuickChange (Stratagene
Inc., La Jolla, CA) mutagenesis was used to introduce
mutations into tat1 and jtat according to the manufactur-
er’s instructions.
Transfections and CAT assays
HeLa or 293 cells were grown in 10-cm plates to
30–50% confluence and cotransfected with 3 g of an
HIV-1 LTR-CAT reporter plasmid, 2 g of a pBKRSV con-
struct expressing one of the different tat genes, and 2 g
of an SV40 -galactosidase control plasmid (pCH110,
Amersham Pharmacia Biotech) using Lipofectamine
transfection reagent (Life Technologies) according to the
manufacturer’s instructions. At 48 h posttransfection, the
cells were washed with PBS, resuspended in 500 l
0.25M Tris–HCl (pH 7.8), and lysed by repeated freezing
and thawing. The protein content of cell lysates was
measured using a modified Bradford assay (Bio-Rad
Laboratories, Regents Park, NSW). -Galactosidase (-
Gal) activity was determined using a chlorophenol red
galactopyranoside assay (Roche Diagnostics Australia).
CAT levels in lysates normalized for transfection effi-
ciency according to -Gal activity were determined using
the Roche Diagnostics CAT ELISA kit. For analysis of
mutated jtat and tat1 genes, 293HIV1tat cells were
grown on 10-cm plates to 30–50% confluence and co-
transfected with the wild-type or mutated tat genes and
pCH110. At 48 h posttransfection, cell-free culture super-
natant was collected for NERT assays and half of the
cells were lysed and analyzed for total protein and -ga-
lactosidase activity. The remaining half of the cells were
used to generate the stably transfected cells.
Ribonuclease protection assay
The run-off RNA probes used in ribonuclease protec-
tion assays were synthesized using T7 Riboprobe re-
agents (Promega Australia, Annandale, NSW), [32P]CTP
(400 Ci/mmol) and pGEM3z or pGEM4z plasmids that
were linearized with restriction enzymes as follows: for
EIAV tat with Sac I, HIV-2 tat with Nde I, JDV tat with Nar
I, HIV-1 tat with Pvu II, HIV-1 genomic RNA probe with
EcoR1. All transcripts were purified from 7.3 M urea/5%
polyacrylamide gels before use. Ribonuclease protection
assays were performed using the RPAII kit (Ambion,
Austin, TX) according to the manufacturer’s instructions.
Briefly, DNase I-treated sucrose cushion-purified virus
containing 100 ng of CA-p24 Ag was solubilized along
with 10 g of purified yeast RNA and a radiolabeled RNA
riboprobe using Trizol reagent (Life Technologies Pty.).
Total cellular RNA was also isolated from each stable
cell line with Trizol reagent and 20 g of this RNA was
mixed with an appropriate riboprobe. The RNA mixtures
were incubated in the hybridization solution at 46°C for 16 h
and digested with a combination of RNase T1 and RNase
A. The digested RNAs were precipitated with ethanol, re-
suspended in the RNA loading dye provided, separated on
denaturing (7.3 M urea) 5% polyacrylamide gels, and visu-
alized and quantitated by PhosphorImager (Amersham
Pharmacia Biotech, Annandale, NSW) analysis.
Natural endogenous reverse transcription assay
Virus stocks were assayed for total RT activity on a
synthetic homopolymer template in the presence of de-
tergent using the RT Detect Assay (Roche Diagnostics
Australia) according to the manufacturer’s instructions.
Aliquots of virus (typically 1.0 mU of RT activity) were
supplemented with 10 mM MgCl2 and incubated for 30
min at 37°C with 100 U of DNase I in a final volume of
200 l of IMDM. Reverse transcription was terminated in
half of the DNase I-treated virus stock by the addition of
150 l of stop solution [10 mM Tris–HCl (pH 7.4), 10 mM
EDTA, 20 mg/ml sheared salmon sperm DNA, and 50
mg/ml proteinase K] followed by incubation at 37°C for
10 min, and then boiling for 10 min. The remaining 100 l
was supplemented with 200 M deoxynucleoside
triphosphates (dNTPs), incubated at 37°C for 90 min, and
then terminated as described above. The stopped reac-
tion mixtures were centrifuged briefly at 14,000 g, and 10
l of each was assayed for negative-strand () strong-
stop DNA by 28–30 cycles of PCR (65°C for 2 min and
93°C for 1 min) using the HIV-1-specific oligonucleotide
primers 96/118 (radiolabeled) (5-CAA GTA GTG TGT
GCC CGT CTG TT, sense) and 158/182 (5-CTG CTA
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GAG ATT TTT CCA CAC TGA C, antisense) in the presence
of 3.5 mM MgCl2 to compensate for EDTA present in the
stop mix. PCR standard curves were generated by ampli-
fying serial dilutions of an HIV-1 proviral plasmid, and all
PCRs were performed in the linear range of the assay.
PCR and DNA sequencing
Chromosomal DNA was isolated from each 293HIV1-
tat cell line and from parental, untransfected 293 cells
using DNAsol reagent (Life Technologies) according to
the manufacturer’s instructions. PCR was performed us-
ing 100 ng of chromosomal DNA and 100 ng each of the
pBKRSV-specific oligonucleotides 5-CGC CGG GTT TTC
CCA GTC ACG AC {M13/pUC (47), forward} and 5-AGC
GGA TAA CAA TTT CAC ACA GGA {M13/pUC (48),
reverse}. HIV-1 DNA encoding the tat gene and flanking
sequences was amplified using the specific oligonucle-
otides 5-GTC GAC ATA GCA GAA TAG GCG TTA C
(HXB2 nt 5786 to 5810, forward) and 5-CCA CTG TCT
TCT GCT CTT TCT ATT AGT CTA TC (HXB2 nt 6222 to
6191, reverse). All PCR products were isolated and se-
quenced directly using Dye Terminator cycle sequencing
technology (Applied Biosystems, Gladsville, NSW).
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